APIM Therapeutics (Norway)

Recent papers from APIM Therapeutics (Norway)

1. Multiple Myeloma Cells with Increased Proteasomal and ER Stress Are Hypersensitive to ATX-101, an Experimental Peptide Drug Targeting PCNACancers · 2024
2. PCNA regulates primary metabolism by scaffolding metabolic enzymesOncogene · 2022
3. ATX-101, a Peptide Targeting PCNA, Has Antitumor Efficacy Alone or in Combination with Radiotherapy in Murine Models of Human GlioblastomaCancers · 2022
4. PCNA has specific functions in regulation of metabolism in haematological cells2020
5. Targeting the non-canonical roles of PCNA modifies and increases the response to targeted anti-cancer therapyOncotarget · 2019
6. “Two hits - one stone”; increased efficacy of cisplatin-based therapies by targeting PCNA’s role in both DNA repair and cellular signalingOncotarget · 2018
7. APIM-peptide targeting PCNA improves the efficacy of docetaxel treatment in the TRAMP mouse model of prostate cancerOncotarget · 2018
8. Increased Anticancer Efficacy of Intravesical Mitomycin C Therapy when Combined with a PCNA Targeting PeptideTranslational Oncology · 2014
9. Targeting Proliferating Cell Nuclear Antigen and Its Protein Interactions Induces Apoptosis in Multiple Myeloma CellsPLoS ONE · 2013